北京大学第三医院副院长

北京大学第三医院血管医学研究所所长

血管稳态与重构全国重点实验室副主任

北京大学人工智能研究院智慧医疗与康养中心主任

唐熠达，教授、主任医师，博士研究生导师。现任北京大学第三医院科研副院长、血管医学研究所常务副所长、医学创新研究院副院长。享受国务院政府特殊津贴，国家杰出青年科学基金获得者，国家百千万人才工程“有突出贡献中青年专家”，教育部长江学者特聘教授，首都科技领军人才。长期从事心血管疾病危重症如心力衰竭和心肌梗死的复合治疗及冠心病高危复杂病变的介入治疗；致力于心脏瓣膜病的微创介入治疗和内外科一站式复合手术；拓展和推动心血管疾病合并代谢紊乱的规范化和个体化诊疗。作为项目负责人先后主持多项重大国家级和省部级科研项目，如“十二五”、“十三五”国家科技支撑计划、973项目子课题、国家杰出青年科学基金、国自然重大研究计划、首都临床特色应用研究重点课题等；牵头组织多项多中心大规模临床研究。致力于心血管领域的创新药物和医疗器械的研发，获得多项国家发明专利和软件著作权，发表一系列高水平文章，主编多部专著。任分子心血管学教育部重点实验室副主任，中华医学会心血管病分会全国委员/代谢性心血管疾病学组组长，中国医疗器械行业协会临床试验分会副主任委员，海峡两岸医药卫生交流协会心血管专业委员会候任主任委员，北京医学会心血管分会副主任委员等。

教育经历:

管理学硕士, 美国约翰霍普金斯大学,  2014.9-2017.7

博士，北京协和医学院, 2000.9-2003.7

硕士，北京协和医学院，1997.9-2000.7

学士，湖南医科大学 (现中南大学湘雅医学院) 1990.7-1995.6

工作经历：

2020/09 至今 教授，主任医师，北京大学第三医院

2008/06 -2020/08   主任医师，中国医学科学院阜外医院

2005/06 -2008/05   博士后、副研究员，美国耶鲁大学医学院心脏内科

2004/06 -2005/06   博士后，美国南达科他大学心脏病研究所

1995/09 -2004/05   主治医师、总住院医师、住院医师，中国医学科学院阜外医院

Yi-Da Tang, MD, PhD

Professor, Vice President

Peking University Third Hospital

Director, Institute of Vascular Medicine, Peking University Third Hospital

Deputy Director, State Key Laboratory of Vascular Homeostasis and Remodeling

Director, Innovative Healthcare and Wellness Research Center, Institute for Artificial Intelligence

Dr. Yi-Da Tang, an interventional cardiologist and scientist, specializes in the clinical diagnosis and treatment of complex coronary artery disease and structural heart diseases. His bench-to-bedside research focuses on studying the pathophysiological mechanisms underlying thyroid dysfunction and myocardial infarction, heart failure, and valvular heart disease, identifying key pathogenic driver of dyslipidemia and atherosclerosis, as well as the prevention of cardiometabolic diseases, such as those with hyperlipidemia, chronic kidney diseases, and thyroid dysfunctions.

Dr. Tang has led a series of pioneering randomized controlled trials on pharmacological therapies for thyroid dysfunction in patients with heart failure and myocardial infarction, as well as novel drug targets for hyperlipidemia. Additionally, he has optimized antithrombotic strategies for high-risk patients after percutaneous coronary intervention and pioneered hybrid surgeries for coronary artery disease combined with aortic dissection.

Dr. Tang also leads collaborative research focusing on artificial intelligence (AI)-facilitated medical applications. His team has developed the "MediGuide" large language model to enhance the triage and early diagnosis of myocardial infarction and heart failure with preserved ejection fraction (HFpEF) stratification, aiming to improve early warning for cardiovascular emergencies, enhancing prediction accuracy and reducing the diagnostic window.

Education

MBA, Johns Hopkins University, USA, 2017

MD, Clinical Medicine, Peking Union Medical College, 2003

Master, Clinical Medicine, Peking Union Medical College, 2000

Bachelor, Clinical Medicine, Xiangya School of Medicine of Central South University, 1995

Research Positions

2020/09 to Current Chief physician, Peking University Third Hospital

2008/06 -2020/08 Chief physician, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

2005/06 -2008/05 Assistant professor, Postdoctoral research fellow, Yale University School of Medicine, Department of Cardiology

2004/06 -2005/06 Postdoctoral research fellow, University of South Dakota, Cardiovascular Research Institute

1995/09 -2004/05 Attending Physician, Chief Resident, Resident, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Publications

1. Chen Li, Chuangshi Wang, Jun Hao, Yitian Zheng, Jie Yang, Wenyao Wang, Yi-Da Tang, Level of evidence supporting the Chinese cardiovascular disease clinical practice guidelines and its evolution in the past two decades, The Lancet Regional Health - Western Pacific, 2023, 100773. (IF =7.1)

2. Zhou Q, Yang J, Tang H, Guo Z, Dong W, Wang Y, Meng X, Zhang K, Wang W, Shao C, Hua X, Tang YD. High triglyceride-glucose (TyG) index is associated with poor prognosis of heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2023 Sep 29;22(1):263. (IF =9.3)

3. Zhou Q, Yang J, Wang W, Shao C, Hua X, Tang YD. The impact of the stress hyperglycemia ratio on mortality and rehospitalization rate in patients with acute decompensated heart failure and diabetes. Cardiovasc Diabetol. 2023 Jul 26;22(1):189. (IF =9.3)

4. Xiong YJ, Du LL, Diao YL, Wen J, Meng XB, Gao J, Shao CL, Wang WY, Zhu XY, Tang YD. Association of dietary inflammatory index with helicobacter pylori infection and mortality among US population. J Transl Med. 2023 Aug 12;21(1):538. (IF =7.4)

5. Yang J, Wang Y, Xi Z, Ma Y, Shao C, Wang W, Tang Y-D. Remnant-Like Particle Cholesterol and the Risk of Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis. Journal of Cardiovascular Development and Disease. 2022; 9(12):452.(IF =4.415)

6. Jie Yang, Yitian Zheng, Chen Li, Jun Gao, Xiangbin Meng, Kuo Zhang, Wenyao Wang, Chunli Shao, Yi-Da Tang#. The impact of the stress hyperglycemia ratio on short-term and long-term poor prognosis in patients with acute coronary syndrome：Insight from a large cohort study in Asia Running title: Association of SHR with cardiovascular prognosis. Diabetes Care, 2022; 45 (4): 947–956. (IF =17.152)

7. Dong C, Yang Y, Wang Y, Hu X, Wang Q, Gao F, Tang YD#. Gut microbiota combined with metabolites reveals unique features of acute myocardial infarction patients different from stable coronary artery disease.  J Adv Res. 2022. (IF=12.822)

8. Zheng, Y., Li, C., Yang, J. Tang YD#. Atherogenic index of plasma for non-diabetic, coronary artery disease patients after percutaneous coronary intervention: a prospective study of the long-term outcomes in China. Cardiovasc Diabetol. 2022; 21: 29. (IF=8.949)

9. Jie Yang, Yitian Zheng, Chen Li, Yu Peng Liu, Qing Zhou, Jun Gao, Xiangbin Meng, Kuo Zhang, Wenyao Wang, Chunli Shao, Yi-Da Tang#. The impact of subclinical hyperthyroidism on cardiovascular prognosis in patients undergoing percutaneous coronary intervention. The Journal of Clinical Endocrinology & Metabolism, 2021, 4: 4. (IF =5.898)

10. Zimin Song, Ruotong Yang, Wenxiu Wang, Ninghao Huang, Zhenhuang Zhuang, Yuting Han, Lu Qi, Ming Xu, Yi-da Tang#, Tao Huang#. Association of healthy lifestyle including a healthy sleep pattern with incident type 2 diabetes mellitus among individuals with hypertension. Cardiovascular Diabetology, 2021; 20:239. (IF =8.949)

11. Yupeng Liu, Jingjing Song, Juan Yang, Jilin Zheng, Ling Yang, Jun Gao, Song Tian, Zhen Liu, Xiangbin Meng, Jian-Cheng Wang, Zhifei Dai, Yi-Da Tang#.  Tumor necrosis factor-α-induced protein 8-like 2 alleviates nonalcoholic fatty liver disease via suppressing TAK1 activation. Hepatology. 2021; 74: 1300-1318.(IF=17.425)

12. Jingjing Song, Yupeng Liu, Juan Wan, Guang-Nian Zhao, Jian-Cheng Wang, Zhifei Dai, Sha Hu, Ling Yang, Zhen Liu, Yi Fu, Erdan Dong, Yi-Da Tang#. SIMPLE is an endosomal regulator that protects against NAFLD by targeting the lysosomal degradation of EGFR. Hepatology. 2021;74:3091-3109.(IF=17.425)

13. Liu Y, Wang W, Song J, Zhang K, Tang YD#. Prognosis of spontaneous myocardial infarction and various definitions of periprocedural myocardial infarction in patients who underwent percutaneous coronary intervention. International Journal of Cardiology.2021;333:60-68.(IF=4.164)

14. Xie M, Tang Y and Hill JA. HDAC inhibition as a therapeutic strategy in myocardial ischemia/reperfusion injury. J Mol Cell Cardiol. 2019;129:188-192. (IF=5.296)

15. Zhang X, Wang WY, Zhang K, Tian J, Zheng JL, Chen J, An SM, Wang SY, Liu YP, Zhao Y, Wang JJ, Yang M and Tang YD#. Efficacy and safety of levothyroxine (L-T4) replacement on the exercise capability in chronic systolic heart failure patients with subclinical hypothyroidism: Study protocol for a multi-center, open label, randomized, parallel group trial (ThyroHeart-CHF). Trials. 2019;20:143.（IF=2.067）

16. Tang YD#*, Wang W, Yang M, Zhang K, Chen J, Qiao S, Yan H, Wu Y, Huang X, Xu B, Gao R, Yang Y and Investigators C. Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial. Circulation. 2018;137:2231-2245. (IF=29.69)

17. Wang S, Yan ZZ, Yang X, An S, Zhang K, Qi Y, Zheng J, Ji YX, Wang PX, Fang C, Zhu XY, Shen LJ, Yan FJ, Bao R, Tian S, She ZG and Tang YD#. Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver. Hepatology. 2018;67:1320-1338. (IF=17.425)

18. Sun P, Zeng Q, Cheng D, Zhang K, Zheng J, Liu Y, Yuan YF and Tang YD#.  Caspase Recruitment Domain Protein 6 protects against hepatic steatosis and insulin resistance by suppressing Ask1. Hepatology. 2018;68:2212-2229.(IF=17.425)

19. Sun P, Lu YX, Cheng D, Zhang K, Zheng J, Liu Y, Wang X, Yuan YF and Tang YD#.  Monocyte chemoattractant protein-induced protein 1 targets hypoxia-inducible factor 1alpha to protect against hepatic ischemia/reperfusion injury. Hepatology. 2018;68:2359-2375. ((IF=17.425)

20. Tang Y*, Qiao S, Su X, Chen Y, Jin Z, Chen H, Xu B, Kong X, Pang W, Liu Y, Yu Z, Li X, Li H, Zhao Y, Wang Y, Li W, Tian J, Guan C, Xu B and Gao R. Drug-Coated Balloon Versus Drug-Eluting Stent for Small-Vessel Disease: The RESTORE SVD China Randomized Trial. JACC Cardiovasc Interv. 2018;11:2381-2392. (IF=9.544)

21. An S, Zhao LP, Shen LJ, Wang S, Zhang K, Qi Y, Zheng J, Zhang XJ, Zhu XY, Bao R, Yang L, Lu YX, She ZG and Tang YD#. USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity. Hepatology. 2017;66:1866-1884.(IF=17.425)

22. Tang YD* and Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation. 2006;113:2454-61.(IF=29.69)

23. Tang YD*, Kuzman JA, Said S, Anderson BE, Wang X and Gerdes AM. Low thyroid function leads to cardiac atrophy with chamber dilatation, impaired myocardial blood flow, loss of arterioles, and severe systolic dysfunction. Circulation. 2005;112:3122-30. (IF=29.69)